Seeking Alpha

Johnson & Johnson (JNJ)

  • Oct. 9, 2012, 7:47 AM
    Johnson & Johnson (JNJ) is cut to Sell with $72 price target at Goldman, which projects just 7% upside for the stock vs. double that for the rest of the pharmaceutical group (see Eli Lilly upgrade). "We see JNJ as lacking transformational pipeline opportunities." Shares -1.2% premarket.
    | Oct. 9, 2012, 7:47 AM | 1 Comment
  • Oct. 8, 2012, 5:16 PM
    Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of its Doxil cancer drug. Under JNJ's plan, existing contract manufacturer Ben Venue Labs would produce Doxil while a second supplier would handle other tasks such as ensuring the drug is sterile.
    | Oct. 8, 2012, 5:16 PM | 1 Comment
  • Oct. 6, 2012, 8:15 AM
    Despite a Dividend 100 Index up 10% in 2012, dividend bargains are there to be had, especially if you look outside the U.S., Brett Arends suggests. And managers point to three attractive sectors in particular: pharmaceuticals, big energy and telecoms. Individual issues like JNJ, T, VZ and some global oil stocks look good, as well as ETFs like IDV, though it may be financials-heavy.
    | Oct. 6, 2012, 8:15 AM | Comment!
  • Sep. 26, 2012, 7:56 AM
    The EU proposes tougher standards on medical devices and implants after investigations showed hundreds of thousands of women were at risk from substandard silicone implants. Independent assessment of manufacturers and increased product testing could result from the new legislation.
    | Sep. 26, 2012, 7:56 AM | 4 Comments
  • Sep. 25, 2012, 4:26 PM
    JNJ promoted illegal marketing of its antipsychotic drug Risperdal by paying physicians to give favorable speeches, subsidizing golf trips and even having sales staff “butter up doctors” with bags of “Risperdal Popcorn,” according to one of its managers in court testimony today. The testimony casts a pall over the company's marketing tactics, which, in addition to the 420 suits currently filed against the company by individuals claiming to have been injured by the drug, are the subject of government probes and Medicare fraud lawsuits filed by state officials.
    | Sep. 25, 2012, 4:26 PM | 5 Comments
  • Sep. 20, 2012, 6:05 AM
    Ten major pharmaceutical firms, including AstraZeneca (AZN), Eli Lilly (LLY), GSK, J&J (JNJ) and Pfizer (PFE), have formed a non-profit organization called TransCelerate BioPharma to cooperate on research as they look to speed up drug development. TransCelerate will start by making clinical trials more efficient, including standardizing the way data is recorded to make it easier for regulators.
    | Sep. 20, 2012, 6:05 AM | Comment!
  • Sep. 18, 2012, 5:26 PM
    JNJ's Janssen Biotech unit requests FDA approval of Simponi, its investigational intravenous formulation for the treatment of adults with moderately to severely active rheumatoid arthritis.
    | Sep. 18, 2012, 5:26 PM | Comment!
  • Sep. 13, 2012, 11:23 AM
    The FDA issues a warning that some consumers have reported receiving serious skin injuries while using certain over-the-counter mild muscle and joint pain relievers containing the active ingredients menthol, methyl salicylate and capsaicin. 43 reported cases of burns have been reported, with the injuries ranging from mild to severe chemical burns. Some of the products named include Sanofi's (SNY -0.1%) Icy Hot and Johnson & Johnson's (JNJ +0.7%) Bengay, among others.
    | Sep. 13, 2012, 11:23 AM | 2 Comments
  • Sep. 13, 2012, 9:01 AM
    Johnson & Johnson (JNJ) hires Bayer CropScience CEO Sandra Peterson to oversee J&J's recall-plagued consumer health and manufacturing operations. Peterson's recruitment is the first major executive hire by Alex Gorsky since he became J&J CEO in April as he looks to make good on a pledge to fix the company's quality, legal and ethical problems. (PR)
    | Sep. 13, 2012, 9:01 AM | 3 Comments
  • Sep. 12, 2012, 9:35 AM
    J&J's (JNJ) and Pfizer' (PFE) bapineuzumab drug showed signs that it is able to reduce nerve-cell damage in the brain and the buildup of amyloid plaque, which has been linked to Alzheimer's disease. While bapineuzumab was unable to improve patients' memory or thinking, as disclosed last month, the drug could eventually be used as a preventative measure.
    | Sep. 12, 2012, 9:35 AM | 1 Comment
  • Sep. 5, 2012, 8:21 AM
    The FDA grants priority review status for Johnson & Johnson's (JNJ) bedaquiline drug, which is a treatment for strains of tuberculosis that are resistant to other multiple drugs. The FDA is expected to decide on bedaquiline in early 2013 after J&J filed for approval in June.
    | Sep. 5, 2012, 8:21 AM | Comment!
  • Aug. 30, 2012, 12:27 PM
    J&J's (JNJ -0.5%) Janssen Pharmaceuticals settles with 36 states and the District of Columbia regarding allegations related to promotional and marketing practices for its anti-psychotic medication Risperdal. Under the terms of the agreement, the company will pay approximately $181M, with predesignated portions to be paid to each state participating in the settlement.
    | Aug. 30, 2012, 12:27 PM | Comment!
  • Aug. 30, 2012, 8:16 AM
    J&J (JNJ) unit Janssen Biotech buys the global licensing rights to cancer agent daratumumab from Danish biotech Genmab in a deal that could eventually be worth over $1.1B. Janssen is paying $55M upfront and will make further payments following the achievement of development, regulatory and sales milestones. J&J is also investing $80M in Genmab in return for a 10.7% stake. (PR)
    | Aug. 30, 2012, 8:16 AM | Comment!
  • Aug. 27, 2012, 10:02 AM
    J&J's (JNJ +0.2%) and Bayer's (BAYRY.PK) Xarelto blood thinner significantly cut cardiovascular death, heart attacks and strokes in patients who have suffered a severe heart attack and when used with with standard treatments. The results came from  a Phase III trial that was testing Xarelto for use in acute coronary syndrome, for which the companies are trying to receive FDA approval after a rejection in June. (PR)
    | Aug. 27, 2012, 10:02 AM | Comment!
  • Aug. 27, 2012, 8:38 AM
    Medtronic's (MDT) Protect study confirms the long-term safety of drug-eluting coronary stents, which slowly release a drug to block cell proliferation. The trial, the largest ever for such products, used Medtronic's Endeavor stent and J&J's (JNJ) Cypher to test for stent thrombosis, when a blood clot forms inside the stent. (PR)
    | Aug. 27, 2012, 8:38 AM | 4 Comments
  • Aug. 23, 2012, 9:35 AM
    GSK and J&J (JNJ) start Phase III trials of sirukumab for treating moderate-to-severe rheumatoid arthritis. Sirukumab is among a number of drugs under development for the multi-billion dollar market for treating RA, which affects 1.5M Americans and 23.5M people globally. (PR)
    | Aug. 23, 2012, 9:35 AM | Comment!
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.